Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Public health genomics wikipedia , lookup
Declaration of Helsinki wikipedia , lookup
Patient safety wikipedia , lookup
Epidemiology wikipedia , lookup
Clinical trial wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Human subject research wikipedia , lookup
19th December 2014_Version 1.0: COPD STARR Studying the different characteristics of chronic obstructive pulmonary disease in primary care using near-patient testing and relating this to treatment responses during an acute exacerbation Internal Reference Number / Short title: COPD: STudying Acute exaceRbations and Responses (COPD STARR) IRAS:151240 Ethics Ref: 15 SC 0025 Date and Version No: 19th December 2014. Version 1.0 Chief Investigator: Dr Mona Bafadhel, University of Oxford [email protected] 01865 612898 Sponsor: University of Oxford Funder: National Institute for Health Research Chief Investigator Signature: Confidentiality Statement There are no conflicts of interest to declare This document contains confidential information that must not be disclosed to anyone other than the Sponsor, the Investigator Team, host organisation, and members of the Research Ethics Committee, unless authorised to do so. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 1 of 40 19th December 2014_Version 1.0: COPD STARR TABLE OF CONTENTS 1. SYNOPSIS ............................................................................................................................................... 5 2. ABBREVIATIONS..................................................................................................................................... 6 3. BACKGROUND AND RATIONALE ............................................................................................................ 7 3.1. Current treatment strategies using corticosteroids and antibiotics ............................................. 7 3.2. Characterising COPD phenotypes.................................................................................................. 8 3.3. Directed treatment using near-patient testing ............................................................................. 9 3.4. Study Rationale.............................................................................................................................. 9 Figure 1. Study rationale ..................................................................................................................... 10 4. OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS ........................................................................ 11 4.1. Study Aims ................................................................................................................................... 11 4.2. Study Objectives .......................................................................................................................... 11 4.3. Study Outcomes............................................................................................................................... 11 4.3. 5. Hypothesis ................................................................................................................................... 11 STUDY DESIGN ..................................................................................................................................... 12 Figure 2. Study schedule...................................................................................................................... 12 Figure 3. Project timelines and Gantt chart ........................................................................................ 13 6. 7. PARTICIPANT IDENTIFICATION ............................................................................................................ 13 6.1. Study Participants ........................................................................................................................ 13 6.1. Inclusion Criteria.......................................................................................................................... 13 6.2. Exclusion Criteria ......................................................................................................................... 14 STUDY PROCEDURES ........................................................................................................................... 14 7.1. Recruitment ................................................................................................................................. 14 7.2. Informed Consent ........................................................................................................................ 15 7.3. Screening and Eligibility Assessment........................................................................................... 15 7.3.1 Pre Screening assessment .......................................................................................................... 15 7.3.2. Screening assessment ............................................................................................................... 15 7.4. Study Assessments ...................................................................................................................... 15 7.4.1 Scheduled baseline visit 1 .......................................................................................................... 16 7.4.2. Unscheduled exacerbation visit 2 (day 0) ................................................................................. 17 7.4.3. Unscheduled exacerbation visit 3 (day 30) ................................................................................... 18 7.4.4. Unscheduled exacerbation visit 4 (day 90) ............................................................................... 19 Figure 4. Study scheduled and unscheduled visit assessments .......................................................... 19 Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 2 of 40 19th December 2014_Version 1.0: COPD STARR 7.5. Discontinuation/Withdrawal of Participants from Study ............................................................ 19 7.6. Definition of End of Study ........................................................................................................... 20 8. SAFETY REPORTING ............................................................................................................................. 20 8.1. Definition of Serious Adverse Events .......................................................................................... 20 8.2. Reporting Procedures for Serious Adverse Events ...................................................................... 20 9. STATISTICS AND ANALYSIS................................................................................................................... 21 9.1. Statistical Plan ............................................................................................................................. 21 9.2. Health Economic Analysis Plan .................................................................................................... 21 10. DATA MANAGEMENT ...................................................................................................................... 22 10.1. Access to Data ......................................................................................................................... 22 10.2. Data Recording ........................................................................................................................ 22 10.3. Data Storage ............................................................................................................................ 22 10.4. Data protection ....................................................................................................................... 22 11. QUALITY ASSURANCE PROCEDURES ............................................................................................... 22 12. ETHICAL AND REGULATORY CONSIDERATIONS............................................................................... 23 12.1. Declaration of Helsinki............................................................................................................. 23 12.2. Guidelines for Good Clinical Practice ...................................................................................... 23 12.3. Approvals ................................................................................................................................. 23 12.4. Reporting ................................................................................................................................. 23 12.5. Participant Confidentiality ....................................................................................................... 23 12.6. Expenses and Benefits ............................................................................................................. 23 13. FINANCE AND INSURANCE .............................................................................................................. 24 13.1. Funding .................................................................................................................................... 24 13.2. Insurance ................................................................................................................................. 24 14. PUBLICATION POLICY....................................................................................................................... 24 15. REFERENCES .................................................................................................................................... 25 16. APPENDIX A: Charlson Co-morbidity index ..................................................................................... 28 17. APPENDIX B: MRC Dyspnoea Scale.................................................................................................. 29 18. APPENDIX C: Visual Analogue Scale (VAS) ....................................................................................... 30 19. APPENDIX D: COPD Assessment Tool (CAT) .................................................................................... 31 20. APPENDIX E: Hospital and Anxiety Depression Scale (HADS) .......................................................... 32 21. APPENDIX F: EuroQol 5D ................................................................................................................. 33 22. APPENDIX G: Standard Operating Procedures ................................................................................ 35 23. Appendix H: 30 day VAS diary card ................................................................................................. 36 Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 3 of 40 19th December 2014_Version 1.0: 24. COPD STARR APPENDIX I: AMENDMENT HISTORY .............................................................................................. 40 Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 4 of 40 19th December 2014_Version 1.0: COPD STARR 1. SYNOPSIS Studying the different characteristics of chronic obstructive pulmonary disease in primary care using near-patient testing and relating this to treatment responses during an acute exacerbation Internal ref. no. / COPD: STudying Acute exaceRbations and Responses (COPD STARR) short title Study Title Study Design Prospective observational cohort study Study Setting Primary & Community Care Study Participants Adults, aged >40 with COPD Planned Sample Size 300 Planned Study Period 12 months – Projected anticipated start date Jan 2015 Objectives Primary Characterise COPD during stable state and exacerbations in primary care Outcomes 1. Measure the incidence of eosinophilic and non-eosinophilic COPD phenotypes in primary care using near-patient testing (blood eosinophil count and C reactive protein) 2. Quantify the proportion of patients that respond (treatment responders) and do not respond (treatment failures) to standard/usual treatment for a COPD exacerbation in primary care and relate to phenotypes of COPD 3. Measure patient reported outcomes (symptoms, health status and healthcare utilisation) following treatment of an exacerbation of COPD 4. Derive pilot data quantifying treatment response following standard treatment of an exacerbation of COPD in primary for a future randomised clinical trial Secondary Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 5 of 40 19th December 2014_Version 1.0: COPD STARR 2. ABBREVIATIONS CAT COPD assessment tool COPD chronic obstructive pulmonary disease CRF case record form CRP c reactive protein FEV1 forced expiratory volume in 1 second FENO fraction exhaled nitric oxide FVC forced vital capacity GMP good medical practice GP general practitioner HADS hospital anxiety and depression scale MRC Medical research council dyspnoea scale MRSA methicillin resistant staphylococcus aureus NNH number needed to harm PI principal investigator PRO patient reported outcome QA quality assurance QC quality control QP quality persons RCT randomised control trial SAE serious adverse event SI sub-investigator TSC trial steering committee VAS visual analogue scale Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 6 of 40 19th December 2014_Version 1.0: COPD STARR 3. BACKGROUND AND RATIONALE Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity and mortality1,2 affecting quality of life and associated with lung function decline3. It is predicted to be the 3rd leading cause of death by 2020 affecting over 200 million people worldwide4. The natural progression of COPD is characterised by progressive airflow obstruction and often punctuated by periods of worsening in respiratory symptoms and function associated with significant impact on quality of life. These episodes are termed exacerbations or lung attacks and represent a large burden on healthcare, accounting for 15% of all U.K acute hospital admissions, 1 million hospital bed days and an estimated annual NHS expenditure of approximately £500 million2. In the U.K, more than 1.4 million GP consultations annually are attributable to COPD exacerbations. It is estimated that there are 130,000 hospitalised exacerbations of COPD annually and approximately 75% of these have been treated by the GP within 4 weeks of admission2. A single acute episode of COPD requiring hospitalisation costs £1,5005 and projected treatment failure costs can accumulate to over £145 million annually. At present there is limited evidence to understand why patients seen and treated by the GP fail treatment within 30 days and require further treatment and admission. There are no primary care studies which have examined whether this sub-group of treated COPD patients have a new or prolonged re-exacerbation event, whether there are detectable prognostic features of worsened outcomes identifying a higher risk of patient or whether there are simple bedside tools that can be used to recognise and predict an adequate or inadequate response to treatment. Current COPD exacerbation treatment strategies rely on oral corticosteroids and antibiotics albeit in an inferior ‘one size fits all’ approach. Furthermore the evidence for the use of corticosteroids and antibiotics during COPD exacerbations is weak6,7 and not without harm8-10. There is currently no guidance available to identify treatment responders in primary care, where the largest proportions of exacerbations are initially and often singly managed. 3.1. Current treatment strategies using corticosteroids and antibiotics The clinical response to treatment varies considerably and is associated with significant side effects. Our current inability to target therapy means some patients are inappropriately treated placing a vulnerable population at further risk. A review of the evidence, in a Cochrane systematic review6, supporting systemic corticosteroids and antibiotics during exacerbations of COPD determined marginal short term improvements without mortality benefits6,7. This Cochrane review showed significant heterogeneity with respect to study protocols, patient attrition and study outcomes. Corticosteroid use is associated with multiple risks including osteoporosis, fractures and hyperglycaemia. The use of corticosteroids in COPD exacerbations is associated with significant harm (number needed to harm (NNH) of 5) and a 5 fold risk of hyperglycaemia; for every 13 persons treated, 1 will develop hyperglycaemia6; with additional costs to the Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 7 of 40 19th December 2014_Version 1.0: COPD STARR NHS related to diabetes and osteoporosis. The widespread use of antibiotic therapy is associated with the production of ‘super bugs’ such as Methicillin Resistant Staphylococcus aureus (MRSA) in addition to antibiotic associated infection (C difficile) and antibiotic related diarrhoea. C difficile rates and detected MRSA bacteraemia (accounting for 22 million and 37 million bed days respectively) is directly related to this blanket use of antibiotics. A 15% reduction in antibiotic usage in 1 year is associated with a 70% reduction in MRSA rates11. Many of the studies, providing the evidence for treatment have focussed on severe or hospitalised exacerbations of COPD. Despite the widespread use of corticosteroid and antibiotic therapy there are no studies investigating outcomes in exacerbations presenting to the GP in primary care. Pathogens such as bacteria and viruses are believed to be the major underlying cause of COPD exacerbations12,13. In primary care, sampling for virus or bacteria at the onset of an exacerbation is not performed and guidance for the prescription of antibiotics is based on symptoms and sputum purulence14 although confounded by the presence of bacterial colonisation15. At present, there is a paucity of randomised antibiotic placebo control studies in mild or moderate primary care exacerbations of COPD to support the practice of withholding antibiotic or therapy. 3.2. Characterising COPD phenotypes Recent trends have advocated the characterisation of COPD phenotypes which relate to clinically meaningful outcomes such as symptoms, exacerbations and responses to treatment in the management of COPD16. The presence of a sputum eosinophilia in stable COPD has been repeatedly associated with a positive clinical response (FEV1 and symptoms) following treatment with oral corticosteroids17-19. A sputum eosinophilia is detected in up to 40% of COPD20, but sputum processing is time consuming and requires specialist skills21. In previous work our research group have determined and validated that the blood eosinophil count is the best surrogate for a sputum eosinophilia during COPD exacerbations22. In a recent biomarker-driven randomised placebo control trial our research group has determined that a high peripheral blood eosinophil count during an exacerbation of COPD (approximately occurring in 50%) was associated with marked clinical and statistically significant improvement in after 14 days of prednisolone therapy compared to non-eosinophilic COPD exacerbation prescribed prednisolone23. Furthermore in a study investigating prognosticators for COPD exacerbations the DECAF index has recently been shown to be a strong predictor of mortality in hospitalised exacerbations of COPD. Importantly, this study confirmed that a low peripheral eosinophil count was an independent predictor of COPD exacerbation mortality 24. Eosinopenia accompanies the acute response to infection and inflammation25. These studies would suggest that the blood eosinophil count may be identifying a treatment responsive and prognostic COPD exacerbation phenotype and may be a simple and useful tool to use in the management of COPD exacerbations in primary care. It is well recognised that antibiotic therapy should be given to bacterial Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 8 of 40 19th December 2014_Version 1.0: COPD STARR infections. In previous work we have also shown that the C reactive protein level (CRP) is the best bedside test to determine whether antibiotics should and should not be prescribed in admissions to hospital with symptoms suggestive of an acute respiratory illness26. In further validation studies, it has been observed that a CRP of above 50 has been found to be associated with the most benefit following antibiotic treatment in hospitalised exacerbations of COPD 27 and is also predictive of a treatment failure in mild to moderate exacerbations28. The combination of these independent findings suggests that the blood eosinophil count and CRP can be used as biomarkers to determine treatment with oral steroids and antibiotics. 3.3. Directed treatment using near-patient testing Near-patient testing in primary care using the peripheral blood eosinophil count and the CRP could be used to guide effective and personalised treatment in patients with COPD. Currently available systems include the Hemocue® 5-point differential cell count system and the QuikRead-go CRP analyser (OxfordBiosystems) which accurately and rapidly (within 2 minutes) determine the peripheral blood eosinophil count and CRP from finger-prick sampling. Hemocue® a leading provider of automated haematology diagnostics, manufacture a portable analyser which provides accurate and rapid (within minutes) cell counts from finger-prick sampling. This diagnostic is currently used in neonatology, A&E and at Mount Everest Base Camp29-31. The fraction of exhaled Nitric Oxide (NiOX MINO®, Aerocrine) is a surrogate measure of eosinophilic airway inflammation and is an approved tool in the management of asthma32. The test requires little skill, is automated and similar to a breathalyser. Children as young as 5 years old have been effective at using it in the paediatric respiratory clinic. However, little is known about its effectiveness in patients with COPD and during an exacerbation and its accuracy as a surrogate marker. Identification of COPD exacerbation phenotypes in primary care using the application of near-patient testing could deliver improvement and targeted antibiotic and corticosteroid therapy. 3.4. Study Rationale It is recognised that the majority of exacerbations that are hospitalised have been seen by their general practitioner in the previous 30 days and received treatment with oral steroids and antibiotics 2. These hospitalisations are effectively treatment failures. Hospitalisations of COPD are associated with increased mortality33, worsened health status34, lung function decline35 and further exacerbations36,37. Eosinophilic COPD exacerbations have greatest improvement with oral steroid therapy23 and severe hospitalised exacerbations have most benefit with antibiotic therapy38. It remains unknown what proportion of inflammatory phenotypes occur in patients attending primary care with an exacerbation of COPD and how many are treatment successes or treatment failures (figure 1). Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 9 of 40 19th December 2014_Version 1.0: COPD STARR Figure 1. Study rationale Near-patient testing in primary care at the initial COPD exacerbation consultation could guide effective and personalised treatment and reduce treatment failures associated with eosinophilic and noneosinophilic exacerbations. To investigate this, an observational study to quantify the proportion of COPD exacerbation phenotypes (eosinophilic and non-eosinophilic exacerbations) and the proportion that have treatment failures with current standard therapy according to eosinophilic and non-eosinophilic phenotypes will be performed. Characterisation of these patients in primary care using questionnaires that relate to the exacerbation (COPD assessment tool39, CAT), the symptoms (visual analogue scale40, VAS), the degree of anxiety or depression (Hospital and anxiety depression score41, HADS) and quality of life (EuroQol 5D42), and simple finger-prick sampling of blood for measurement of eosinophils and CRP can facilitate understanding these treatment failures. This work will then derive pertinent data for a future randomised controlled trial to determine if a personalised stratified medicine approach using near-patient testing could be used to deliver therapy for patients with COPD exacerbations in primary care leading to strategies to aid the right treatment for the right patient at the right time. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 10 of 40 19th December 2014_Version 1.0: COPD STARR 4. OBJECTIVES AND OUTCOME MEASURES/ENDPOINTS 4.1. Study Aims To study and understand the characteristics of patients with COPD exacerbations in a primary care setting. 4.2. Study Objectives Characterise COPD during stable state and exacerbations in primary care 4.3. Study Outcomes 1. Measure the incidence of eosinophilic and non-eosinophilic COPD phenotypes in primary care using near-patient testing (blood eosinophil count and CRP) 2. Quantify the proportion of patients that respond (treatment responders) and do not respond (treatment failures) to standard/usual treatment for a COPD exacerbation in primary care and relate to phenotypes of COPD 3. Measure patient reported outcomes (symptoms, health status and healthcare utilisation) following treatment of an exacerbation of COPD 4. Derive pilot data quantifying treatment response following standard treatment of an exacerbation of COPD in primary for a future randomised clinical trial 4.3. Hypothesis We hypothesise that the non-selective non-phenotype specific treatment of an exacerbation leads to a failure to respond to standard treatment of a COPD exacerbation (also called a treatment failure). Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 11 of 40 19th December 2014_Version 1.0: COPD STARR 5. STUDY DESIGN Study design: Prospective observational cohort study Setting: This will be conducted in a single centre large primary care practice and in the community. The recorded number of patients registered within the GP surgery geographical area is approximately 24,000 and the practice has 367 COPD registered patients. The community based nursing team are in charge of admission avoidance for COPD patients in the geographical area of the primary care practice. Study duration: 12 months data collection and 3 months analyses Data collection: Demographic and full medical history, including smoking history, exacerbation history and medication history. Clinic based spirometry, pulse oximetry, quality of life questionnaires (CAT, VAS, HADS, EuroQoL) and inflammatory phenotype based on finger-prick sampling and lung function. Study schedule: Baseline stable visit to record demographic, severity, symptom and inflammatory measurements. Exacerbation visit as defined by GP or Community Nursing Team. Medical history and management as per usual treatment by responsible team; research review thereafter for inflammation phenotype and symptomology. Telephone visit consultation for symptomology and treatment failure episodes (figure 2). Figure 2. Study schedule Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 12 of 40 19th December 2014_Version 1.0: COPD STARR Project timelines It is anticipated that subject recruitment, follow up and data cleaning will be completed over 15 months. The timeline for the project is outlined in the Gantt figure 3. Figure 3. Project timelines and Gantt chart Time (months) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Ethics Application and Approval Subject recruitment Subject follow up Data Cleaning and Data Lock Data Analysis Dissemination & Public engagement 6. PARTICIPANT IDENTIFICATION 6.1. Study Participants Adults (age > 40) with a diagnosis of COPD attending primary care or Community respiratory nurse review at stable state or with an acute exacerbation of COPD necessitating a course of systemic corticosteroids and/or antibiotic therapy will be recruited to enter the study. Patients with COPD having an annual review with their general practitioner for reasons other than a COPD exacerbation will also be invited for nearpatient testing and characterisation by the study staff which will also include inhaler technique, smoking cessation advice and as an aide-mémoire to enrich the exacerbation population. The participant population, inclusion and exclusion criteria in this observational study are listed below. 6.1. Inclusion Criteria Participant is willing and able to give informed consent for participation in the study Male or Female, aged 40 years or above. Known diagnosis of COPD (either diagnosis made in primary or secondary care) as per national and international guidelines1,2, irrespective of severity Current or Ex-Smoker Smoking pack year history >10 Spirometry confirming fixed airflow obstruction (FEV1/FVC ratio <0.7) Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 13 of 40 19th December 2014_Version 1.0: COPD STARR 6.2. Exclusion Criteria History of atopic childhood asthma Current history of primary lung malignancy or current active pulmonary TB HIV, hepatitis B or C positive (will be part of initial screening eligibility from medical notes) Clinically relevant disease or disorder (past or present) which in the opinion of the investigator may either put the subject at risk because of participating in the study or may influence the results of the study or the subject’s ability to participate in the study. Any clinically relevant lung disease, other than COPD considered by the investigator to be the primary diagnosis. For example mild-to-moderate bronchiectasis is acceptable in addition to COPD unless the bronchiectasis is considered to be the primary diagnosis. An alternative cause for the increase in symptoms of COPD that are unrelated to an exacerbation such as i) suspicion or clinical evidence of pneumonia; ii) high probability and suspicion of pulmonary embolism; iii) suspicion or clinical evidence of a pneumothorax; iv) primary ischaemic event – ST or Non ST elevation myocardial infarct and left ventricular failure [i.e. not an exacerbation of COPD] 7. STUDY PROCEDURES 7.1. Recruitment Within primary care, as part of the quality and outcomes framework (QOF) for managing long term common and chronic conditions, GP’s annually perform spirometry and identify patients with respiratory disease. Within this identification procedure, all primary care practices nationally have COPD registers. At the selected practice, there are 367 patients with COPD on the register. This will identify COPD participants immediately, with invitation letters joint directly from the study team and the GP surgery. In addition to this, the community respiratory admission avoidance team, funded by both the local NHS hospital and the Clinical Commissioning Group for the relevant area, are also responsible for 350 patients with COPD who have direct access to the nursing team (including home visits and referrals locally) during periods of worsening of their symptoms. These patients can also be identified immediately and invited to take part in the research via invitation letters. Screening for suitability will be available directly from GP medical records for the primary care COPD registered patients and from the community care nursing team notes. Study specific adverts will be left in the primary care practice. All patients suitable for observation will be invited to take part. Assuming a recruitment response of 50% from screening we will aim to recruit 300 patients. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 14 of 40 19th December 2014_Version 1.0: COPD STARR 7.2. Informed Consent The participant must personally sign and date the latest approved version of the Informed Consent form before any trial specific procedures are performed. Written and verbal versions of the Participant Information and Informed Consent will be presented to the participants detailing no less than: the exact nature of the trial; what it will involve for the participant; the implications and constraints of the protocol; the known side effects and any risks involved in taking part. It will be clearly stated that the participant is free to withdraw from the trial at any time for any reason without prejudice to future care, and with no obligation to give the reason for withdrawal. The participant will be allowed as much time as wished to consider the information and the opportunity to question the Investigator, their GP or other independent parties to decide whether they will participate in the trial. Written Informed Consent will then be obtained by means of participant dated signature and dated signature of the person who presented and obtained the Informed Consent. The person who obtained the consent must be suitably qualified and experienced, and have been authorised to do so by the Chief/Principal Investigator. A copy of the signed Informed Consent will be given to the participant. The original signed form will be retained at the trial site. 7.3. Screening and Eligibility Assessment 7.3.1 Pre Screening assessment Primary care GP and community nursing records will be used to identify eligible participants including confirmation of diagnosis, inclusion and exclusion criteria (during the participant stable state of disease). 7.3.2. Screening assessment At the screening visit participants will be given the opportunity to ask the research staff any questions they have about the study prior to providing informed written consent. Participants will be informed that they can withdraw from the research project at any time without prejudice to further care. No pre-specified screening procedures are required for subject recruitment in this observational study and upon provision of consent participants will be asked to confirm eligibility and study assessments will be undertaken. 7.4. Study Assessments Study assessments will be performed within the primary care practice by the research team or within the community (at home) by the community respiratory nursing staff. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 15 of 40 19th December 2014_Version 1.0: COPD STARR 7.4.1 Scheduled baseline visit 1 Demographic history: Participant demographics including age, smoking history and past COPD medical history will be collected. Medication history: Full medication history will be collected, including the use of as required and over the counter medication. Any drug allergy will be documented and dates of flu vaccination, S. pneumoniae and H. influenzae B vaccinations will be recorded from medical records. Past medical history: Full medical history will be collected from the participant and from the medical notes. The Charlson Comorbidity Index43 (CCI) will be calculated [detailed in appendix A] . COPD diagnosis history: The age of onset and age of diagnosis of COPD symptoms will be recorded from the participant and from the medical records. Past exacerbation history: The frequency of exacerbations, including those requiring hospitalisation in the previous 12 months will be captured from participant recollection and from the medical records. Medication prescribed at each exacerbation event (if available) from medical records will be captured. Questionnaires: Patient reported outcome measures (PRO’s) will be sought to specifically test symptoms, health status, quality of life and any associated depression and anxiety. This will utilise the use of the Medical Research Council dyspnoea scale (MRC, Appendix B); Visual analogue score (VAS, Appendix C) 40; COPD Assessment Tool (CAT, Appendix D) 44; the Hospital Anxiety and Depression Scale (HADS, Appendix E)41 and the EuroQol 5D (Appendix F)42. Instructions to use these questionnaires will be given to all participants. Each of these questionnaires are validated to be self-completed for ease of use. Near-patient point of care testing procedures: Lung Function: Spirometry will be performed to determine the forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC) according to standard ATS/ERS criteria45. Exhaled Nitric Oxide: FENO will be used to determine airway inflammation. Participants are instructed to blow into a machine for 10 seconds at tidal volume (normal breathing). The FENO will be available immediately. Pin prick testing: Using a fully sterile technique, a pin-prick blood test will be performed to determine the inflammatory phenotype. Approximately 5 drops of blood (up to a maximum of 10 drops) will be taken for measurement of peripheral blood eosinophil counts and CRP levels. Sputum Collection: If the participant produces any sputum during the visit it will be collected into a sterile container and processed the same day for measurement of sputum cell differential counts and Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 16 of 40 19th December 2014_Version 1.0: COPD STARR microbiology. Any cell free supernatants will be stored for cell mediator analysis. These samples will be stored and used in a number of analytical ways not limited to but including cell isolation for functional assays, cell differential counts, and preparation of supernatants for mediator analysis. The samples will also be used in microbiological analysis for assessment of pathogens which may include bacteriology, virology and mycology. Development of analytical methods will be devised. Methods will include, but will not be restricted to, immunocytochemistry, flow cytometry, ELISA, radioimmunoassay, LC/MS and proteomics. Pulse Oximetry: Oxygen saturations at rest will be recorded on all participants and available immediately. This is performed by putting a non-invasive probe on the participants’ finger and recording the reading at 30 seconds. Standard operating procedures for the near-patient point of care testing is presented in Appendix G. All research staff undertaking any assessments and procedures will be trained to use the equipment and perform the questionnaires to determine patient reported outcomes. Anticipated duration of visit is 30 to 45 minutes. 7.4.2. Unscheduled exacerbation visit 2 (day 0) Study assessments will be performed on participants attending to see their GP or community respiratory team for management of an exacerbation of COPD after medical assessment and treatment as per usual care with medication dispensed or prescribed as per standard guidelines. After this healthcare review, participants will be invited and seen by the research team. The anticipated duration will be 30 minutes. Exacerbation history: Collection of data specific to the exacerbation with respect to symptom type, duration and severity and details regarding which medication has been prescribed and its duration. During an exacerbation the Anthonisen criteria14 with increased symptoms of breathlessness, sputum production and sputum purulence will be used as per GOLD1 definition. The Anthonisen criteria for severity of an exacerbation will be used as follows: Type 1 – Three major symptoms; Type 2 - two major symptoms; Type 3 – One major and one minor symptom. The major symptoms are i) Increased breathlessness; ii) increased sputum production; or iii) increased sputum purulence. The minor symptoms are iv) Upper respiratory tract infection in the previous 5 days; v) fever without apparent cause; vi) increased wheeze; vii) increased cough; viii) increase in respiratory or heart rate 20% above baseline. Questionnaires: This will utilise the use of the Visual analogue score (VAS, Appendix C)40; COPD Assessment Tool (CAT, Appendix D) 44; and the EuroQol 5D (Appendix F)42. Instructions to use these questionnaires will be given to all participants. Each of these questionnaires are validated to be self-completed for ease of use. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 17 of 40 19th December 2014_Version 1.0: COPD STARR Diary Card: Participants will be asked to complete a 30-day daily diary (using the VAS tool, for the symptoms of cough, breathlessness, and sputum volume and purulence) for assessment of symptoms and recovery following treatment (Appendix H). Guidance will be given on how to complete this and a selfaddressed envelope addressed to the research centre. Lung Function: If possible spirometry will be performed to determine the forced expiratory volume in 1 second (FEV1) and the forced vital capacity (FVC) according to standard ATS/ERS criteria45. Exhaled Nitric Oxide: If possible FENO will be used to determine airway inflammation. Participants are instructed to blow into a machine for 10 seconds at tidal volume (normal breathing). The FENO will be available immediately. Pin prick testing: Using a fully sterile technique, a pin-prick blood test will be performed to determine the inflammatory phenotype. Approximately 5 drops of blood (up to a maximum of 10 drops) will be taken for measurement of peripheral blood eosinophil counts and CRP levels. Sputum Collection: If the participant produces any sputum during the visit it will be collected into a sterile container and processed the same day for measurement of sputum cell differential counts and microbiology and assessed as described above. Pulse Oximetry: Oxygen saturations at rest will be recorded on all participants and available immediately. This is performed by putting a non-invasive probe on the participants’ finger and recording the reading at 30 seconds. 7.4.3. Unscheduled exacerbation visit 3 (day 30) This is a telephone consultation to ascertain any history of a treatment response or treatment failure following the exacerbation event utilising PRO’s and medical records. A treatment failure is defined as the need for re-treatment, further use of standby home packs, emergency attendances, hospitalisation or the event of death of any cause. The telephone consultation will have an anticipated duration of 15 minutes. All participants will be encouraged to post back their completed 30-day VAS diary at this telephone consultation. Medical notes, prescription dispensing and hospitalised episode data will be interrogated for collection of any treatment failure episodes. Questionnaires: Participants will be interviewed using the following PRO’s; Visual analogue score (VAS, Appendix C)40; COPD Assessment Tool (CAT, Appendix D) 44; and the EuroQol 5D (Appendix F)42. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 18 of 40 19th December 2014_Version 1.0: COPD STARR 7.4.4. Unscheduled exacerbation visit 4 (day 90) A final telephone consultation with PRO’s to ascertain any history of a treatment response or treatment failure will be conducted with an anticipated duration time of 15 minutes. Medical notes, prescription dispensing and hospitalised episode data will be again interrogated for collection of any treatment failure episodes. Questionnaires: Participants will be interviewed using the following PRO’s; Visual analogue score (VAS, Appendix C)40; COPD Assessment Tool (CAT, Appendix D) 44; and the EuroQol 5D (Appendix F)42. Participants who have a further exacerbation within 30 days of the index exacerbation event will be categorised as a treatment failure episode and recorded as such. Participants that have an exacerbation between days 30 to 90 of the index exacerbation event will be invited to attend and have data captured as a new exacerbation event and the visit schedule is then restarted as per figure 2. The planned study assessments and study schedule is presented in figure 4. Figure 4. Study scheduled and unscheduled visit assessments Scheduled Unscheduled Unscheduled Unscheduled Visit 1 Visit 2 Visit 3 Visit 4 X X X X X X Demographics X Medical history X Exacerbation history X X Medication history X X Treatment response history Questionnaires X X Exhaled NO X X Spirometry X X Pin prick blood test X X Sputum X X Symptom Diary X 7.5. Discontinuation/Withdrawal of Participants from Study Participants are free to withdraw consent and may be discontinued from study assessments at any time, at the discretion of the investigator. Reasons for withdrawal/exclusion by researcher are specified as noncompliance with study requirements or health issues that compromise ongoing involvement. Participants will be asked on withdrawal from any of the interventions whether they are still willing to provide follow- Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 19 of 40 19th December 2014_Version 1.0: COPD STARR up information at day 30 and day 90. If they decline, no further information will be collected. The reason for withdrawal will be recorded in the CRF. If the participant is withdrawn due to an adverse event, the Investigator will arrange for follow-up visits or telephone calls until the adverse event has resolved or stabilised. No further procedures or observations will be necessary following study withdrawal and withdrawn participants will not be replaced. Data from withdrawn participants will not be excluded from study analysis. The reason for withdrawal will be recorded in the CRF. 7.6. Definition of End of Study The end of trial participation is the day 90 (visit 4) which will be a final telephone consultation. The study duration will be 12 months data collection with an additional 3 month period for data analysis. 8. SAFETY REPORTING 8.1. Definition of Serious Adverse Events A serious adverse event is any untoward medical occurrence that: results in death is life-threatening requires inpatient hospitalisation or prolongation of existing hospitalisation results in persistent or significant disability/incapacity consists of a congenital anomaly or birth defect. Other ‘important medical events’ may also be considered serious if they jeopardise the participant or require an intervention to prevent one of the above consequences. NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe. 8.2. Reporting Procedures for Serious Adverse Events Exacerbations of COPD requiring treatment, admission to hospital or resulting in death are anticipated occurrences during the disease course and one of the outcomes of investigation in this study. Thus serious adverse events (SAEs) or adverse events causing discontinuation in the study will be only recorded. These Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 20 of 40 19th December 2014_Version 1.0: COPD STARR SAE’s will be reported to the chief investigator or a designated clinician and assessed for any causal link between the intervention delivered within the clinical trial and the serious adverse event. All SAE’s will be reported using the NRES Serious Adverse Event form. 9. STATISTICS AND ANALYSIS In this observational study, we will be collecting data to characterise COPD phenotypes. All participant data will be used. Listwise or pairwise deletion will be used for missing data in these analysis, thereby the data analysis will be complete case analysis. The planned number of participants for this study is 300. There are 367 COPD patients at the selected primary care practice and 350 COPD patients under the community respiratory team. Assuming a retention of 50%, from the pool of 717 patients we will recruit approximately 300 patients over a 12 month period. 9.1. Statistical Plan Descriptive statistics will be used to summarise the baseline characteristics of participants and parametric or non-parametric t-tests (including Mann Whitney) will be used to compare outcomes between the inflammatory phenotypes in relation to disease severity, exacerbation history, treatment history, patient reported outcomes and results of near patient inflammation. Fisher’s exact test and logistic regression modelling will be applied to study the treatment failure episodes and relate this to inflammatory phenotypes. Length of recovery of exacerbation visits will be analysed using a Kaplan Meier survival analysis estimator. 9.2. Health Economic Analysis Plan Patient-level resource use data, including associated treatment costs (such as physician and nurse time, oral corticosteroids, antibiotics, other medications, finger-prick tests), all additional health and personal social service costs (such as visits to emergency walk-in centres, A&E and hospital admissions) as well as leisure and productivity loss due to ill health for participants, will be collected and analysed. Unit costs from the UK, will be derived from national published sources and unit cost schedules and the impact of their use in valuing resource utilization in the economic analyses will be explored. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 21 of 40 19th December 2014_Version 1.0: COPD STARR 10. DATA MANAGEMENT 10.1. Access to Data Direct access will be granted to authorised representatives from the Sponsor or host institution for monitoring and/or audit of the study to ensure compliance with regulations. 10.2. Data Recording All participants will be provided with a unique identifier, which is anonymised on all CRF’s and the electronic database. All data collected will be stored on CRF’s and then entered onto a password protected computer. CRF data will be held in a secure site separate to the unique identifier code issued on recruitment. Any collected sputum samples will be stored anonymously, identified by the unique identifier only. A link between the unique identifiers and personal information will be held in secure conditions in a separate file at the research center, and only the CI will have access to this. 10.3. Data Storage Study data will be carefully reviewed and, before any final analysis, clean file/database lock must be documented. The reason for any excluded data will be described in detail in the report. Any changes in the database after clean file/database lock will be documented. 10.4. Data protection Documents will be stored securely as per ethical consideration and only study staff and authorised personnel will be granted access to data. The study will comply with relevant data protection and privacy legislation. As part of study consent, participants will authorise the anonymous collection, use and disclosure of their study data by the Investigator and by those persons who need that information for the purposes of the study. 11. QUALITY ASSURANCE PROCEDURES The study may be monitored, or audited in accordance with the current approved protocol, ICH GCP, relevant regulations and standard operating procedures. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 22 of 40 19th December 2014_Version 1.0: COPD STARR 12. ETHICAL AND REGULATORY CONSIDERATIONS 12.1. Declaration of Helsinki The Investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki. 12.2. Guidelines for Good Clinical Practice The Investigator will ensure that this study is conducted in accordance with relevant regulations and with Good Clinical Practice. 12.3. Approvals The protocol, informed consent form, participant information sheet and any proposed advertising material will be submitted to an appropriate Research Ethics Committee (REC), and host institution(s) for written approval. The Investigator will submit and, where necessary, obtain approval from the above parties for all substantial amendments to the original approved documents. 12.4. Reporting The CI shall submit once a year or on request, an Annual Progress Report to the REC, host organisation and Sponsor. In addition, an End of Trial notification and final report will be submitted to the REC, host organisation and Sponsor. 12.5. Participant Confidentiality The trial staff will ensure that the participants’ anonymity is maintained. The participants will be identified only by initials and a participants ID number on the CRF and any electronic database. All documents will be stored securely and only accessible by trial staff and authorised personnel. The trial will comply with the Data Protection Act, which requires data to be anonymised as soon as it is practical to do so. 12.6. Expenses and Benefits Reasonable travel expenses for any visits additional to normal care will be reimbursed on production of receipts, or a mileage allowance provided as appropriate. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 23 of 40 19th December 2014_Version 1.0: COPD STARR 13. FINANCE AND INSURANCE 13.1. Funding This study is funded by the National Institute of Health Research via a personal fellowship award to Dr Mona Bafadhel, the Chief and Principal Investigator. The award from the NIHR is to fund the observational study and then to undertake a multi-centre randomised primary care based clinical trial utilising the pilot data obtained from the observational study necessary to adequately power the clinical trial. 13.2. Insurance The University of Oxford has a specialist insurance policy in place which would operate in the event of any participant suffering harm as a result of their involvement in the research (Newline Underwriting Management Ltd, at Lloyd’s of London). NHS indemnity operates in respect of the clinical treatment which is provided. 14. PUBLICATION POLICY The final results of the study will be submitted for publication in peer-reviewed scientific journals for publication and dissemination. Authorship will be determined in accordance with the ICMJE guidelines and other contributors will be acknowledged. All data will be anonymised for publication. Public dissemination of the study results will be via patient led organisations such as the British Lung Foundation and the Breathe Easy groups. Patient and Public Involvement (PPI) will be specifically sought to address dissemination of results and compilation of an end of study newsletter to the participants. Contractual stipulation for the funding body is that the NIHR will be notified prior to publication (oral, written or other form) of the research data. The CI shall send one draft copy of the proposed publication to the NIHR Authority’s Representative at the same time as submission for publication or at least 28 days before the date intended for publication whichever is earlier. The CI shall ensure that the outcome of the Research is prepared for publication in a suitable peer-reviewed journal and shall ensure that it, and any other publication, including patent applications, of or resulting from research carried out under this Contract shall acknowledge the Authority’s financial support and carry a disclaimer as the Authority may require or in the absence of direction from the Authority a notice as follows: “This report is independent research supported by the National Institute for Health Research (PostDoctoral Fellowship, Dr Mona Bafadhel, PDF-2013-06-052). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.” Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 24 of 40 19th December 2014_Version 1.0: COPD STARR 15. REFERENCES 1. West JB. GOLD Executive Summary. American journal of respiratory and critical care medicine 2013;188:1366-7. 2. NICE. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre | Available from http://guidance.nice.org.uk/CG101/Guidance/pdf/English. 2010. 3. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128:1995-2004. 4. WHO. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. World Health Organization| Available at: http://whqlibdoc.who.int/publications/2007/9789241563468_eng.pdf. 2007. 5. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respiratory medicine 2002;96:700-8. 6. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. The Cochrane database of systematic reviews 2009:CD001288. 7. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane database of systematic reviews 2012;12:CD010257. 8. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. The New England journal of medicine 1999;340:1941-7. 9. Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. The New England journal of medicine 2003;348:2618-25. 10. Rothberg MB, Pekow PS, Lahti M, Brody O, Skiest DJ, Lindenauer PK. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA : the journal of the American Medical Association 2010;303:2035-42. 11. Molstad S, Erntell M, Hanberger H, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10-year follow-up of the Swedish Strama programme. The Lancet infectious diseases 2008;8:12532. 12. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. The New England journal of medicine 2008;359:2355-65. 13. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. American journal of respiratory and critical care medicine 2006;173:1114-21. 14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Annals of internal medicine 1987;106:196-204. 15. Soler N, Ewig S, Torres A, Filella X, Gonzalez J, Zaubet A. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 1999;14:1015-22. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 25 of 40 19th December 2014_Version 1.0: 16. COPD STARR Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. American journal of respiratory and critical care medicine 2010;182:598-604. 17. Shim C, Stover DE, Williams MH, Jr. Response to corticosteroids in chronic bronchitis. The Journal of allergy and clinical immunology 1978;62:363-7. 18. Pizzichini E, Pizzichini MM, Gibson P, et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. American journal of respiratory and critical care medicine 1998;158:1511-7. 19. Brightling CE, Monteiro W, Ward R, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2000;356:1480-5. 20. Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. International journal of chronic obstructive pulmonary disease 2006;1:39-47. 21. Pavord ID, Sterk PJ, Hargreave FE, et al. Clinical applications of assessment of airway inflammation using induced sputum. The European respiratory journal Supplement 2002;37:40s-3s. 22. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. American journal of respiratory and critical care medicine 2011;184:662-71. 23. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. American journal of respiratory and critical care medicine 2012;186:48-55. 24. Steer J, Gibson J, Bourke SC. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease. Thorax 2012. 25. Bass DA, Gonwa TA, Szejda P, Cousart MS, DeChatelet LR, McCall CE. Eosinopenia of acute infection: Production of eosinopenia by chemotactic factors of acute inflammation. The Journal of clinical investigation 1980;65:1265-71. 26. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011;139:1410-8. 27. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2010;181:150-7. 28. Llor C, Moragas A, Hernandez S, Bayona C, Miravitlles M. Efficacy of Antibiotic Therapy for Acute Exacerbations of Mild to Moderate COPD. American journal of respiratory and critical care medicine 2012. 29. Hobbs FD, Delaney BC, Fitzmaurice DA, et al. A review of near patient testing in primary care. Health technology assessment 1997;1:i-iv, 1-229. 30. Casey JR, Pichichero ME. A comparison of 2 white blood cell count devices to aid judicious antibiotic prescribing. Clinical pediatrics 2009;48:291-4. 31. Grocott MP, Martin DS, Levett DZ, et al. Arterial blood gases and oxygen content in climbers on Mount Everest. The New England journal of medicine 2009;360:140-9. 32. Network BTSSIG. British guideline on the management of asthma. Thorax 2014;69:i1-i192. 33. Suissa S, Dell'Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012;67:957-63. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 26 of 40 19th December 2014_Version 1.0: 34. COPD STARR Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 1998;157:1418-22. 35. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52. 36. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2009;179:369-74. 37. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England journal of medicine 2010;363:1128-38. 38. Puhan MA, Vollenweider D, Latshang T, Steurer J, Steurer-Stey C. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respiratory research 2007;8:30. 39. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. The European respiratory journal 2009;34:648-54. 40. Brightling CE, Monterio W, Green RH, et al. Induced sputum and other outcome measures in chronic obstructive pulmonary disease: safety and repeatability. Respiratory medicine 2001;95:999-1002. 41. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361- 70. 42. EuroQol--a new facility for the measurement of health-related quality of life. The EuroQol Group. Health policy 1990;16:199-208. 43. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987;40:373-83. 44. Mackay AJ, Donaldson GC, Patel AR, Jones PW, Hurst JR, Wedzicha JA. Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. American journal of respiratory and critical care medicine 2012;185:1218-24. 45. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. The European respiratory journal 2005;26:319-38. 46. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH. The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. British medical journal 1959;2:257-66. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 27 of 40 19th December 2014_Version 1.0: COPD STARR 16. APPENDIX A: Charlson Co-morbidity index Serum Albumin (g/dL) ☐ Age <40 years 0 points ☐ Age 41‐50 years 1 points ☐ Age 51‐60 years 2 points ☐ Age 61‐70 years 3 points ☐ Age 71‐80 years 4 points 1 Point ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ ☐ Myocardial Infarction (history, not ECG changes only) Congestive Heart Failure Peripheral Vascular Disease Cerebrovascular Disease: CVA with mild or no residua TIA Dementia COPD Connective Tissue Disease Peptic Ulcer Disease Mild Liver Disease (without portal hypertension, includes chronic hepatitis) Diabetes without end-organ damage (excludes diet-controlled alone) 2 Points ☐ ☐ ☐ ☐ ☐ ☐ Hemiplegia Moderate to Severe Chronic Kidney Disease Diabetes with end-organ damage (retinopathy, neuropathy, nephropathy, or brittle diabetes) Tumor without metastasis (exclude if > 5yrs from diagnosis) Leukemia Lymphoma 3 Points ☐ Moderate or severe liver disease 6 Points ☐ Metastatic solid tumor ☐ AIDS (not just HIV positive) Calculating Charlston’s co-morbidity 1. Calculate Charlson Score or Index (i) 1. Add Comorbidity score to age score 2. Total denoted as 'i' below 2. Calculate Charlson Probablity (10 year mortality) 1. Calculate Y = e^(i * 0.9) 2. Calculate Z = 0.983^Y 3. where Z is the 10 year survival Online calculator of the Charlson score - http://touchcalc.com/calculators/cci_js Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 28 of 40 19th December 2014_Version 1.0: COPD STARR 17. APPENDIX B: MRC Dyspnoea Scale The MRC dyspnoea scale is a standardised instrument to quantify the disability associated with breathlessness 46. Respondents are asked what degree of breathlessness they have related to a set if standardised exercises. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 29 of 40 19th December 2014_Version 1.0: COPD STARR 18. APPENDIX C: Visual Analogue Scale (VAS) The visual analogue scale is a standardised tool 40 to quantify the degree of symptoms specified from a scale of no symptoms to the worst ever symptoms. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 30 of 40 19th December 2014_Version 1.0: COPD STARR 19. APPENDIX D: COPD Assessment Tool (CAT) The CAT is a validated short (8-item) patient completed questionnaire to measure health status specifically in patients with COPD 39 Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 31 of 40 19th December 2014_Version 1.0: COPD STARR 20. APPENDIX E: Hospital and Anxiety Depression Scale (HADS) Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 32 of 40 19th December 2014_Version 1.0: COPD STARR 21. APPENDIX F: EuroQol 5D Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 33 of 40 19th December 2014_Version 1.0: COPD STARR The EQ-5D is a standardised instrument for the measurement of health utility and used for health economic applications Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 34 of 40 19th December 2014_Version 1.0: COPD STARR 22. APPENDIX G: Standard Operating Procedures Exhaled Nitric Oxide (NO) Nitric oxide is widely distributed in the body. Relevant to the lung is the production of nitric oxide in the presence of eosinophilic airway inflammation. Exhaled NO is only produced when inflammation is present and can be measured within the clinic in a few minutes. Participants have to inhale deeply and then exhale through a disposable filter for 10 seconds. The results are available within 2 minutes, with normal values ranging between 5 and 25 parts per billion (ppb). The following factors can cause an increase in the FeNO: airway viral infection, allergic rhinitis and recent consumption of nitrate rich food (beetroot, strawberries, gooseberries and raspberries). A decrease in FeNO can be caused by repeated spirometric measures (thus FeNO is performed before lung function), exercise and smoking. Spirometry The forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and slow vital capacity (SVC) will be measured at each visit using standard spirometry. Spirometry measurements will be obtained using spirometry equipment that meets or exceeds the minimal performance recommendations of the American Thoracic Society45. For FEV1 and FVC determinations, at least 3 acceptable spirometry efforts (with no more than 8) should be obtained. Acceptable spirometry efforts should have a satisfactory start of test and end of test (i.e. a plateau in the volume-time curve) and be free from artefacts due to cough, early termination, poor, obstructed mouthpiece, equipment malfunction, or other reasons. Calibration records will be kept as source documentation. At stable visits whenever possible both pre and post-bronchodilator data measurements will be recorded. At exacerbation only post-bronchodilator measurements of FEV1 and FVC will be captured. Near patient pin-prick blood sampling Near patient test analysis will be performed using the HemoCue WBC DIFF® and QuikRead® CRP analyser. This provides the blood differential cell count and CRP within a few minutes from a very small amount of blood (10μL, equivalent to 1 finger-prick blood spot for each test). Using a completely sterile technique, prick the lateral edge of the proximal third of the digit for sampling and sample according to the manufacturer’s recommendations. COPD Assessment Tool (CAT) The COPD Assessment is a validated, short and simple patient completed questionnaire which has been developed for use in routine clinical practice to measure the health status of patients with COPD 39. The CAT is an 8-item questionnaire suitable for completion by all patients diagnosed with COPD. When completing the questionnaire, subjects rate their experience on a 6-point scale, ranging from 0 (maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores indicate greater disease impact. Visual Analogue Scale (VAS) The VAS is a 100 mm length line where patients will simply mark on the line how they feel from no symptom to worst ever. This will be measured using a ruler and recorded in the eCRF. VAS will be measured for dyspnoea, cough, and sputum production (volume) and sputum purulence (colour) and has been validated for use in COPD patients40. EuroQoL 5D (EQ-5D-5L) The EQ-5D-5L is a standardised instrument for use as a measure of health utility. It is designed for selfcompletion and is cognitively simple, taking only a few minutes to complete. The EQ-5D-5L is a two-part self-assessment questionnaire. The first part consists of five items covering five dimensions (mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression). Each dimension is measured by a fivepoint Likert scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). Respondents are asked to choose one level that reflects their "own health state today" for each Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 35 of 40 19th December 2014_Version 1.0: COPD STARR of the five dimensions. Respondents can be then classified into one of 243 distinct health states. The second part is a 20-cm visual analogue scale (EQ-VAS) that has endpoints labelled "best imaginable health state" and "worst imaginable health state "anchored at 100 and 0, respectively. Respondents are asked to indicate how they rate their own health by drawing a line from an anchor box to that point on the EQ-VAS which best represents their own health on that day. EQ-5D-5L health states are converted to a single summary index by applying a formula that essentially attaches weights to each of the levels in each dimension. The formula is based on the valuation of EQ-5D health states from general population samples. Modified Medical Research Council Dyspnoea Scale (mMRC) The MRC dyspnoea scale is a simple method used to assess the severity of breathlessness46. Graded 0 to 4 patients are asked to choose one of 4 statements relating to the severity of breathlessness. The higher the score the worse the breathlessness. Charlson Co-Morbidity Index (CCI) The Charlson comorbidity index43 is a tool used to predict the ten-year mortality for a patient who may have a range of comorbid conditions, such as heart disease or cancer (a total of 22 conditions). Each condition is assigned a score and a total score is allocated to provide a total score to predict mortality. 23. Appendix H: 30 day VAS diary card Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 36 of 40 19th December 2014_Version 1.0: VAS COPD STARR ID:______Initials: Date Started: A Visual Analogue Scale (VAS) is an instrument used to try to measure a characteristic or attitude that cannot easily be directly measured, e.g. how you feel. This questionnaire is to be taken each day and should only take approximately 5 minutes of your time. There are four sections, each with a different symptom – Cough, Breathlessness, amount of sputum you produce and how discoloured your sputum is. We would like to know how good or bad you feel that symptom are on each day after your treatment has started. For example, if on day 1 your cough is not bad, place a mark on the line towards the left hand side or if was really bad then place the mark towards the right hand side. Do this for each symptom each day. Once the 30 days has finished please pop the diary in the envelope provided and place it in your local post box. We would like to say thank-you for taking the time to fill in this questionnaire Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 37 of 40 19th December 2014_Version 1.0: No Cough COPD STARR Worst Cough Imaginable Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 No Breathlessness CONFIDENTIAL Page 38 of 40 Worse Breathlessness Imaginable 19th December 2014_Version 1.0: No Sputum Production COPD STARR Worse Sputum Production Imaginable Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 No sputum discolouration CONFIDENTIAL Page 39 of 40 Worse Sputum Discolouration Imaginable 19th December 2014_Version 1.0: COPD STARR 24. APPENDIX I: AMENDMENT HISTORY Amendment Protocol No. Version No. Date issued Author(s) of Details of Changes made changes Protocol amendments must be submitted to the Sponsor for approval prior to submission to the REC committee or MHRA. Clinical Research Protocol Template version 8.2 © Copyright: The University of Oxford and Oxford University Hospitals NHS Trust 2013 CONFIDENTIAL Page 40 of 40